Please assess the completion status of the following clinical trial:

Trial Title: Booster and Catch-up Vaccination With Vaccine GSK1024850A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects for whom the investigator believes that their parent(s)/ guardian(s) can and will comply with the requirements of the protocol.~* Written, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~For primed subjects:~* Completion of the full vaccination course in study NCT00814710.~* 9-18 months of age at the time of randomization.~* Group A: 9-18 months of age at the time of booster vaccination.~* Group B: 15-18 months of age at the time of booster vaccination.~For unprimed subjects (Group C):~* Enrolled in study NCT00814710.~* 12-18 months of age at the time of first vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product within 30 days preceding the vaccination, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.~* Administration of immunoglobulins and/or any blood products within three months preceding the vaccination or planned administration during the study period.~* Administration of any pneumococcal vaccine since the end of study NCT00814710.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
- Group B (Type: EXPERIMENTAL): Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
- Group C (Type: EXPERIMENTAL): Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).